Accendra Health, Inc. (ACH)

NYSEHealth CareMedical - DistributionSnapshot 2026-09-04

$1.21-0.82%

Close 2026-09-04 · 1-day change

Standing thesis

The standing, falsifiable read: what has to stay true, and what would break it.

Turnaround

Broken: Primary pillar broken — Revenue near $2.55B to $2.65B in FY26: FY26 revenue guidance $2.45B-$2.55B vs target $2.55B.

The bull case

Accendra Health aims to generate free cash flow of $90M to $110M in 2026. The company affirms revenue guidance near $2.6B and adjusted EBITDA around $345M. Despite recent revenue declines, management maintains its outlook. Share buybacks signal confidence in future cash flow.

The bear case

Revenue is expected to decline about 1% next year. Recent earnings and guidance cuts show pressure on profits. Litigation and debt refinancing raise financial risks. Free cash flow remains negative and volatile.

What's priced in

The market expects about -1% revenue growth and has priced in a weak outlook. Our fair value near $21.67 suggests the stock is cheap versus peers. We differ by cautiously watching free cash flow recovery and revenue stabilization.

What has to stay true

Adjusted EBITDA between $335M and $355M in FY26Broken
Marginprimarybetween $335M and $355M · FY26 (guidance)
Breaks if: adjusted EBITDA falls below $335M in FY26
Are they delivering?Mixed this quarter· 1 tracked commitment
- Affirm revenue and EBITDA guidance for 2026Growth
  Maintain full-year 2026 financial guidance with revenue between $2.45B-$2.55B and adjusted EBITDA of $300M-$320M, targeting breakeven to slightly positive free cash flow.
  Mixed

Source: QuarterlyIQ research model· Written 2026-07-08· Health checked 2026-09-04· Version 1· Status: Broken· Reviewed when the evidence changes

This is not a price target or investment advice.

Current Outlook

Week of Sep 5, 2026

A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.

ACH's long-term thesis remains intact despite recent challenges.

What kind of bet this is

This is a turnaround investment with a focus on improving financial performance. The current thesis state reflects mixed management execution and strong recent results, but the company is still loss-making.

What's priced into Accendra Health, Inc. (ACH)

The market seems to have priced in a level of fragility, given the low expectations gap compared to peers. Valuation is considered cheap versus its industry, indicating that some positive developments may not be fully reflected.

What the fundamentals likely do

Management's commitment to affirming revenue and EBITDA guidance is a key focus, though execution has been mixed. Recent financial performance has shown strength, but the company remains at risk due to its high volatility and loss-making status.

What Accendra Health, Inc. (ACH) hinges on

The thesis hinges on management's ability to meet financial targets and the overall performance of the healthcare sector. Key forward scenarios include potential earnings guidance cuts or positive momentum from sector leaders.

What changed in the latest read

What changed

The most important moves since the prior daily snapshot.

Short-term · Daily

score change · valuation_score
small change
Valuation fell by 10.1 points (from 57.6 to 47.5).

Mixed, the news cuts both ways. The company is advancing its CEO succession planning. However, there was a recent earnings miss that raises concerns about guidance.

as of 2026-09-04

See upcoming information that could change the risk

Review the evidence to watch, what would become a concern, and what would make it less concerning.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.